Wait, don't miss out on the latest GovCon industry news!

Sign Up Now! GovCon Wire provides you with Daily Updates and News Briefings

*By clicking "Join us now" you agree to receive email, promotions and general messages from GovCon Wire, In addition, you also agree to GovCon Wire Privacy Policy and Terms & Conditions.

X Remind me Later

Eli Lilly Receives $625M Army Contract Modification for COVID-19 Antibody Therapy

Eli Lilly and Co. (NYSE: LLY) has secured a $625 million contract modification to supply 500,000 more doses of the company’s COVID-19 monoclonal antibody drug to the U.S. Army.

Army Contracting Command obligated the full amount of the modification using fiscal 2021 Coronavirus Aid, Relief and Economic Security Act funds, the Department of Defense said Wednesday.

In November, the Food and Drug Administration granted emergency use authorization for Lilly’s LY-CoV555 antibody drug as a treatment for patients 12 years and older who have mild to moderate COVID-19 and at risk of developing severe coronavirus infection.

Bamlanivimab is intended to be administered via intravenous infusion, the company noted.

Video of the Day

GovCon Wire Logo

Sign Up Now! GovCon Wire provides you with Daily Updates and News Briefings about Contract Awards

Related Articles